Background We aimed to assess the efficacy and safety of two neutralising monoclonal
antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-…

Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination
hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to …

Victoria J. Davey is deputy chief officer for public health and environmental hazards at the
Department of Veterans Affairs in Washington, DC, and a doctoral student at Uniformed …

Smallpox Vaccination to Prevent Mpox In this report, the effect of temporally remote smallpox
vaccination on subsequent development of mpox was assessed, and modest protection was …

Background The optimal community-level approach to control pandemic influenza is
unknown. Methods We estimated the health outcomes and costs of combinations of 4 social …

Background Respiratory protection relies heavily on user compliance to be effective, but
compliance among health care personnel is less than ideal. Methods In 2008, the Department …

Background The US government proposes pandemic influenza mitigation guidance that
includes isolation and antiviral treatment of ill persons, voluntary household member quarantine …

Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led
to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur …

Background There is a clinical need for therapeutics for COVID-19 patients with acute
hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-…

… Victoria J. Davey served as lead for funding acquisition and contributed equally to data
curation and served in a supporting role for writing (review and editing).Correspondence …